La descarga está en progreso. Por favor, espere

La descarga está en progreso. Por favor, espere

Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis  David González.

Presentaciones similares


Presentación del tema: "Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis  David González."— Transcripción de la presentación:

1 Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis  David González de Olano, MD, Iván Álvarez-Twose, MD, María I. Esteban-López, MD, Laura Sánchez-Muñoz, MD, PhD, María D. Alonso Díaz de Durana, MD, Arantza Vega, MD, PhD, Andres García-Montero, MD, PhD, Eloina González-Mancebo, MD, PhD, Teresa Belver, MD, María D. Herrero-Gil, MD, Montserrat Fernández-Rivas, MD, PhD, Alberto Orfao, MD, PhD, Belén de la Hoz, MD, PhD, Mariana C. Castells, MD, PhD, Luis Escribano, MD, PhD  Journal of Allergy and Clinical Immunology  Volume 121, Issue 2, Pages (February 2008) DOI: /j.jaci Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Evolution of specific-IgE values throughout the years undergoing VIT. Differences between baseline determination and following years: # versus ∗P < .041; # versus ∗∗P < .002; # versus ∗∗∗P < .005; # versus ∗∗∗∗P < .003. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions


Descargar ppt "Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis  David González."

Presentaciones similares


Anuncios Google